{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126276","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.231652+00:00","generated_at":"2026-05-30T01:09:12.395751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AN2 Therapeutics reports Q3 2024 net loss $12.7M, positive Phase 2 epetraborole PRO data in TR-MAC","bullets":["Net loss $12.7M in Q3 2024 vs $16.7M in Q3 2023; cash $93.4M, expected to fund operations through 2027.","Phase 2 portion of EBO-301: epetraborole achieved nominally significant improvements in QOL-B (p=0.0365) and MACrO2 (p=0.0433) vs placebo.","Company plans to meet FDA in H1 2025 to discuss reinitiating Phase 3 TR-MAC study and top-line Phase 3 data in mid-2025.","Achieved 50% reduction in expenditures through strategic realignment; R&D expenses decreased to $8.3M from $14.4M.","Advancing boron chemistry pipeline: Chagas Phase 1 mid-2025, melioidosis Phase 2 enrollment H2 2025, and Gates Foundation grant."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126276","json":"https://secwatch.observer/filing/0000950170-24-126276.json","markdown":"https://secwatch.observer/filing/0000950170-24-126276.md","text":"https://secwatch.observer/filing/0000950170-24-126276.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024126276/0000950170-24-126276-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024126276/antx-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:09:12.395751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}